Funded Health Care Startups in Paris
Among the 29 Paris-area health care rounds shown (spanning 2020-05-11 to 2025-04-03), one disclosed amount stands out: Padoa’s $90M round on 2022-02-02 (Ve…
Among the 29 Paris-area health care rounds shown (spanning 2020-05-11 to 2025-04-03), one disclosed amount stands out: Padoa’s $90M round on 2022-02-02 (Venture – Series Unknown). That $90M figure is far above the next-largest disclosed amounts, with Moon Surgical at $55M (2023-05-17, Series B) and Tricares at $47M (2022-09-16, Series C). The list also shows a tighter temporal cluster in 2023, where many of the larger rounds land between 2023-05-02 and 2023-11-22 (e.g., Moon Surgical $55M on 2023-05-17; Corwave $28M on 2023-06-20; Innerskin $6M on 2023-11-17). Stage naming is inconsistent: 8 of the 29 entries are labeled Series Unknown (including Chipiron $1M on 2024-04-01 and Maddie $1M on 2023-05-02), while 2025 entries skew smaller at the disclosed level (Parallel 1245 $4M on 2025-04-03 vs. Robeaute $28M on 2025-01-14).
Most recent rounds
29 shownRelated listings
Frequently asked
What’s the largest disclosed funding round in this Paris health care list, and how extreme is it versus the rest?
Padoa’s $90M on 2022-02-02 (Venture – Series Unknown) is the only disclosed round at that level in the 29-row view. The next-largest disclosed amounts are Moon Surgical’s $55M (2023-05-17) and Tricares’s $47M (2022-09-16), making $90M an outlier well above the rest of the disclosed range.
Do these rounds cluster in time, especially around 2023?
Yes, 2023 contains multiple mid-to-larger rounds packed into a few months: Moon Surgical closed $55M on 2023-05-17; Corwave $28M on 2023-06-20 (same date as Braintale’s $5M, Series Unknown); and Callyope’s $2M on 2023-11-22, with Innerskin $6M following on 2023-11-17. The overall span runs from 2020-05-11 (Medicaim) to 2025-04-03 (Parallel 1245).
How should a buyer/investor think about stage labeling here—does “Series Unknown” show up often?
Series Unknown appears in 8 of 29 rows, so a meaningful share of round stage labels are not standardized in the data. Examples include Chipiron $1M (2024-04-01), Braintale $5M (2023-06-20), and Maddie $1M (2023-05-02), which can complicate stage-based comparisons.
Is there a clear stage mix pattern among disclosed rounds (Seed vs A vs later rounds)?
Seed rounds appear repeatedly (e.g., Parallel 1245 $4M on 2025-04-03; Callyope $2M on 2023-11-22; Via Sana $6M on 2023-09-19; Oneleaf $5M on 2023-01-24), while later stages also recur (Series B/C/D among the larger ticket rounds like Moon Surgical $55M in 2023 and LimFlow SA $39M in 2022). At the high end, the largest disclosed rounds are not concentrated solely in one later-stage label, with Moon Surgical (Series B) and Tricares (Series C) both sitting far above the mid-tier amounts.
Are there notable outliers on the low end, and what are the smallest disclosed amounts?
The smallest disclosed amount is $1M, appearing on multiple rows with different stage labels, including Chipiron ($1M, 2024-04-01, Series Unknown), Steto ($1M, 2023-11-10, Seed), Maddie ($1M, 2023-05-02, Series Unknown), and Medicaim ($1M, 2020-05-11, blank stage). This creates a low-end floor at $1M while the top end is separated by the $90M Padoa outlier.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.